NVNO · XBRL financial data

enVVeno Medical financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (NVNO's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Research and development	2,981*	3,052	2,825	2,859	3,513*	2,557	2,891	2,585	1,948*	2,111	2,076	2,876
Selling, general and administrative	3,297*	2,451	2,629	3,311	3,186*	2,397	4,158	2,298	2,065*	1,951	1,720	1,658
Operating income (loss)	(6,278)*	(5,503)	(5,454)	(6,170)	(6,699)*	(4,954)	(7,049)	(4,883)	(4,013)*	(4,062)	(3,796)	(4,534)
Net income (loss)	(5,649)*	(4,992)	(4,956)	(5,642)	(6,229)*	(4,503)	(6,694)	(4,539)	(3,736)*	(3,849)	(3,600)	(4,367)
Earnings per share, basic USD per share	—	(0.31)	(0.31)	(0.35)	(0.31)*	(0.22)	(0.33)	(0.23)	—	(5.89)	(5.37)	(6.29)
Earnings per share, diluted USD per share	—	(0.31)	(0.31)	(0.35)	(0.31)*	(0.22)	(0.33)	(0.23)	—	(5.89)	(5.37)	(6.29)
Weighted average shares, basic thousands of shares	—	16,057	16,067	16,067	20,354*	20,352	20,352	20,155	—	654	671	694
Weighted average shares, diluted thousands of shares	—	16,057	16,067	16,067	20,354*	20,352	20,352	20,155	—	654	671	694

† Share count changed about 1/31 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (NVNO's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	3,620	2,314	2,380	17,915	1,754	2,937	2,044	1,544	3,065	2,597	2,841	2,585
Short-term investments	42,792	40,628	36,687	30,464	41,399	36,004	33,098	29,408	25,147	22,333	18,645	15,887
Prepaid and other current assets	511	306	469	672	581	538	462	547	614	559	596	548
Total current assets	46,923	43,248	39,536	49,051	43,734	39,479	35,604	31,499	28,826	25,489	22,082	19,020
Property and equipment, net	334	289	252	218	182	142	113	82	51	16	78	62
Right-of-use asset	1,347	1,261	1,176	1,090	1,007	925	829	740	654	561	469	376
Total assets	48,635	44,829	40,995	50,390	44,954	40,577	36,577	32,352	29,562	26,097	22,660	19,489
Accounts payable	—	—	—	—	1,006	—	—	—	358	813	540	1,080
Total current liabilities	1,371	1,487	1,695	2,229	2,095	1,661	3,015	2,400	2,122	2,143	1,887	2,589
Lease liability, non-current	1,064	973	882	791	700	609	505	505	310	207	103	—
Total liabilities	2,435	2,460	2,577	3,020	2,795	2,270	3,520	2,905	2,432	2,350	1,990	2,589
Accumulated deficit	(130,036)	(135,028)	(139,984)	(145,626)	(151,855)	(156,358)	(163,052)	(167,591)	(171,327)	(175,176)	(178,776)	(183,143)
Total stockholders' equity	46,200	42,369	38,418	47,370	42,159	38,307	33,057	29,447	27,130	23,747	20,670	16,900
Total liabilities and equity	48,635	44,829	40,995	50,390	44,954	40,577	36,577	32,352	29,562	26,097	22,660	19,489
Common shares outstanding (cover page) thousands of shares	13,317	13,330	13,330	17,536	17,536	17,536	19,247	20,216	656	668	683	695

† Share count changed about 1/31 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (NVNO's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(5,649)*	(4,992)	(4,956)	(5,642)	(6,229)*	(4,503)	(6,694)	(4,539)	(3,736)*	(3,849)	(3,600)	(4,367)
Stock-based compensation	1,144*	1,115	1,005*	1,003*	1,018*	651	1,444*	688*	637*	467	397*	410*
Net cash from operating activities	(4,973)*	(3,549)	(3,908)*	(4,276)*	(5,105)*	(4,018)	(3,715)*	(4,392)*	(3,443)*	(3,238)	(3,549)*	(3,178)*
Purchases of property and equipment	4*	10	14*	9*	4*	—	—	0*	0*	—	—	—
Net cash from investing activities	(22,144)*	2,197	3,974*	6,220*	(11,056)*	5,201	2,822*	3,651*	4,182*	2,770	3,667*	2,735*
Proceeds from issuing common stock	year only	—	—	—	—	—	—	—	year only	—	—	—
Net cash from financing activities	year only	46	0*	13,591*	0*	—	—	—	782*	—	—	187*
Net change in cash	(1,326)*	(1,306)	66*	15,535*	(16,161)*	1,183	(893)*	(500)*	1,521*	(468)	244*	(256)*

† Share count changed about 1/31 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
enVVeno Medical	2,585	not reported	(3,178)*	694,826	5.6 quarters	Q3 FY26 10-QSep 30, 2026
TELA Bio	30,424	19,291	(9,381)*	44.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Apyx Medical	27,617	13,884	(3,490)*	42.1M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Spectral AI	14,000	3,524	(4,097)*	32.2M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Sensus Healthcare	15,186	2,290	(3,133)*	16.5M	4.8 quarters	Q2 FY26 10-QJun 30, 2026
Lucid Diagnostics	33,404	not reported	(11,297)*	203.2M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Pro Dex	11,759	20,560	6,490	3.2M	—	Q1 FY27 10-QSep 30, 2026
Accuray	40,623	100,919*	2,427*	119.4M	—	Q4 FY26 10-KJun 30, 2026
Orchestra BioMed Holdings	20,472	88	(19,332)*	60.1M	5.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.